Resistance to ceftaroline - 2018 review

  • Rafał Ślusarczyk Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland
  • Ada Bielejewska Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce,
  • Arkadiusz Bociek Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland
  • Martyna Bociek Faculty of Medical Science, Higher School of Economics, Law and Medical Science of Professor Edward Lipiński, Kielce, Poland
Keywords: Antibiotic, Antibiotic resistance, MRSA, Resistant strains, Ceftaroline-resistant

Abstract

Ceftaroline is a new fifth generation cephalosporin, active mostly against Gram-positive cocci, e.g. Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus). It is used in treating acute bacterial skin and skin structure infections, community acquired respiratory tract infections and methicillin-resistant S. aureus bacteremia. The main resistance mechanisms of bacteria to β-lactam antibiotics, including ceftaroline, are mutations in PBP2a, PBP3 and PBP4. Clinically significant resistance has been noted among both archived and newly-isolated strains in a laboratory test using serial passages. Ceftaroline-resistant strains have also been found in patients suffering from cystic fibrosis, ventilator-associated pneumonia and infectious endocarditis. Irresponsible antibiotic treatment using ceftaroline or other antibiotics (due to a possibility of a cross-resistance) can lead to the spread of ceftaroline resistance and, consequently, its loss of value.

DOI: http://dx.doi.org/10.5281/zenodo.1304435

References

1. Lim L, Sutton E, Brown J. Ceftaroline: a new broad-spectrum cephalosporin. Am J Heal Pharm. 2011; 68: 491-498.

2. Ghamrawi RJ, Neuner E, rehm SJ. Ceftaroline fosamil: A super-cephalosporin? Cleve Clin J Med. 2015; 82: 437-444.

3. Cercenado E, Morosini MI. Espectro antimicrobiano de ceftarolina. Actividad in vitro frente a estafilococos resistentes a la meticilina. Enferm Infecc Microbiol Clin. 2014; 32: 8-14.

4. Rolston KVI, Jamal MA, Nesher L, Shelburne SA, Raad I, Prince RA. In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients. Int J Antimicrob Agents. 2017; 49: 416-421.

5. Shirley D-AT, Heil EL, Johnson JK. Ceftaroline fosamil: a brief clinical review. Infect Dis Ther. 2013; 2: 95-110.

6. Gaikwad V, Gohel T, Panickar S, Chincholkar V, Mangalkar S. In vitro activity of ceftaroline: a novel antibiotic against methicillin-resistant Staphylococcus aureus. Indian J Pathol Microbiol. 2016; 59: 496.

7. Scott LJ. Ceftaroline fosamil: a review in complicated skin and soft tissue infections and community-acquired pneumonia. Drugs. 2016; 76: 1659-1674.

8. Cheung RP, DiPiro JT. Vancomycin: an update. Pharmacotherapy. 1986; 6: 153-169.

9. Pigrau C. [Oxazolidinones and glycopeptides]. Enferm Infecc Microbiol Clin. 2003; 21: 157-164; quiz 165, 169.

10. Mélard A, Garcia LG, Das D, Rozenberg R, Tulkens PM, Van Bambeke F, et al. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin. J Antimicrob Chemother. 2013; 68: 648-658.

11. Taboada M, Melnick D, Iaconis JP, Sun F, Zhong NS, File TM, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2016; 71: 862-870.

12. Livermore DM, Warner M, Mushtaq S. Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant pneumococci. Int J Antimicrob Agents. 2014; 43: 131-134.

13. Allergan Receives FDA Approval of TEFLARO® (ceftaroline fosamil) for Pediatric Patients - Allergan n.d. https://www.allergan.com/news/news/thomson-reuters/allergan-receives-fda-approval-of-teflaro-ceftaro (accessed April 14, 2018).

14. Pfaller MA, Mendes RE, Castanheira M, Flamm RK, Jones RN, Sader HS. Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals. Pediatr Infect Dis J. 2017; 36: 486-491.

15. Borgmann S, Rieß B, von Wernitz-Keibel T, Matthias Buehler M, Strommenger B, Layer F. Recovery of a 10-year-old girl from methicillin-resistant Staphylococcus aureus sepsis in response to low-dose ceftaroline treatment. Ther Clin Risk Manag. 2016; 12: 749.

16. Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, et al. A multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2016; 61: AAC.02015-16.

17. White BP, Barber KE, Stover KR. Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Am J Heal Pharm. 2017; 74: 201-208.

18. Werth BJ, Barber KE, Ireland CE, Rybak MJ. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/ pharmacodynamic model of simulated endocardial vegetation. Antimicrob Agents Chemother. 2014; 58: 3177-3181.

19. Shafiq I, Bulman ZP, Spitznogle SL, Osorio JE, Reilly IS, Lesse AJ, et al. A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA). Infect Dis (Auckl). 2017; 49: 410-416.

20. Jongsma K, Joson J, Heidari A. Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report. J Antimicrob Chemother. 2013; 68: 1444-1445.

21. Harrison EM, Ba X, Blane B, Ellington MJ, Loeffler A, Hill RLR, et al. PBP2a substitutions linked to ceftaroline resistance in MRSA isolates from the UK. J Antimicrob Chemother. 2016; 71: 268-269.

22. Lahiri SD, McLaughlin RE, Whiteaker JD, Ambler JE, Alm RA. Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus : the role of PBP2a in the activity of ceftaroline. J Antimicrob Chemother. 2015; 70: 2488-2498.

23. Long SW, Olsen RJ, Mehta SC, Palzkill T, Cernoch PL, Perez KK, et al. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2014; 58: 6668-6674.

24. Abbott IJ, Jenney AWJ, Jeremiah CJ, Mirčeta M, Kandiah JP, Holt DC, et al. Reduced in vitro activity of ceftaroline by etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia. Antimicrob Agents Chemother. 2015; 59: 7837-7841.

25. Lahiri SD, Alm RA. Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs. J Antimicrob Chemother. 2016; 71: 3050-3057.

26. Chan LC, Basuino L, Diep B, Hamilton S, Chatterjee SS, Chambers HF. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015; 59: 2960-2963.

27. Lavanya P, Ramaiah S, Anbarasu A. A molecular docking and dynamics study to screen potent anti-staphylococcal compounds against ceftaroline resistant MRSA. J Cell Biochem. 2016; 117: 542-548.

28. Schaumburg F, Peters G, Alabi A, Becker K, Idelevich EA. Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA. J Antimicrob Chemother. 2016; 71: 41-44.

29. Kelley WL, Jousselin A, Barras C, Lelong E, Renzoni A. Missense mutations in PBP2A affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998. Antimicrob Agents Chemother. 2015; 59: 1922-1930.

30. Lahiri SD, Alm RA. Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline. J Antimicrob Chemother. 2016; 71: 34-40.

31. Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, et al. Evolution of ceftaroline-resistant MRSA in a child with cystic fibrosis following repeated antibiotic exposure. Pediatr Infect Dis J. 2016; 35: 813-815.

32. Tschierske M, Mori C, Rohrer S, Ehlert K, Shaw KJ, Berger-Bächi B. Identification of three additional femAB-like open reading frames in Staphylococcus aureus. FEMS Microbiol Lett. 1999; 171: 97-102.

33. Rohrer S, Ehlert K, Tschierske M, Labischinski H, Berger-Bächi B. The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation. Proc Natl Acad Sci USA. 1999; 96: 9351-9356.

34. Greninger AL, Chatterjee SS, Chan LC, Hamilton SM, Chambers HF, Chiu CY. Whole-genome sequencing of methicillin-resistant Staphylococcus aureus resistant to fifth-generation cephalosporins reveals potential non-mecA mechanisms of resistance. PLoS One. 2016; 11: e0149541.

35. Nigo M, Diaz L, Carvajal LP, Tran TT, Rios R, Panesso D, et al. Ceftaroline-resistant, daptomycin-tolerant, and heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus causing infective endocarditis. Antimicrob Agents Chemother. 2017; 61: e01235-16.

36. Pfaller MA, Mendes RE, Flamm RK, Jones RN, Sader HS. Ceftaroline activity against multidrug-resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and molecular characterization of a single ceftaroline nonsusceptible isolate. Microb Drug Resist. 2017; 23: 571-579.

37. Andrey DO, François P, Manzano C, Bonetti EJ, Harbarth S, Schrenzel J, et al. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013–2014 at the Geneva University Hospitals. Eur J Clin Microbiol Infect Dis. 2017; 36: 343-350.

38. Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF. In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme. J Antimicrob Chemother. 2016; 71: 162-169.

39. Zhang H, Xiao M, Kong F, O’Sullivan MVN, Mao L-L, Zhao H-R, et al. A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: Susceptibility to ceftaroline and molecular epidemiology. Int J Antimicrob Agents. 2015; 45: 347-350.

40. Abbott IJ, Jenney AWJ, Jeremiah CJ, Mirčeta M, Kandiah JP, Holt DC, et al. Reduced in vitro activity of ceftaroline by E-test among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia. Antimicrob Agents Chemother. 2015; 59: 7837-7841.
Published
2018-07-03
How to Cite
Ślusarczyk, R., Bielejewska, A., Bociek, A., & Bociek, M. (2018). Resistance to ceftaroline - 2018 review. European Journal of Biological Research, 8(3), 112-120. Retrieved from http://www.journals.tmkarpinski.com/index.php/ejbr/article/view/77
Section
Review Articles